Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of ODM-104 compared to a standard combination (Stalevo); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson's disease and end-of-dose wearing-off

Next Previous
Search
Trial Profile

Efficacy and safety of ODM-104 compared to a standard combination (Stalevo); a randomised, double-blind, crossover proof-of-concept study in patients with Parkinson's disease and end-of-dose wearing-off

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ODM 104 (Primary) ; Carbidopa; Levodopa; Levodopa/carbidopa/entacapone
  • Indications Parkinson's disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms COMPOC
  • Sponsors Orion

    • Most Recent Events

    • 24 Oct 2018 Primary endpoint has been met. (Duration of daily OFF-time (measured by Hauser ON/OFF-diary)), according to an Orion media release.
    • 18 Jul 2018 According to an Orion media release, the company is continuing analysis of results from this trial.
    • 04 Apr 2018 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top